Table 1.
Baseline, disease, transplantation and GVHD characteristics of patients with SR aGVHD in two groups
| Variable | MSC group No. (%) |
Control group No. (%) |
P |
|---|---|---|---|
| No. of patients | 99 | 99 | |
| Age, median (range), years | 28 (16–59) | 29 (16–57) | 0.680 |
| < 18 year | 14 | 17 | |
| ≥ 18 year | 85 | 82 | |
| Sex | 0.385 | ||
| Male | 62 (62.6%) | 56 (56.6%) | |
| Female | 37 (37.4%) | 43 (43.4%) | |
| Disease | 0.129 | ||
| AML | 39 (39.4%) | 49 (49.5%) | |
| ALL | 45 (45.5%) | 43 (43.4%) | |
| Others* | 15 (15.2%) | 7 (7.1%) | |
| MDS | 6 (6.1%) | 3 (3.0%) | |
| CML | 3 (3.0%) | 1 (1.0%) | |
| MM | 1 (1.0%) | 0 | |
| NHL | 0 | 1 (1.0%) | |
| Other acute leukemia | 5 (5.1%) | 2 (2.0%) | |
| Disease status at transplant | 0.524 | ||
| CR | 63 (63.6%) | 70 (70.7%) | |
| PR | 6 (6.1%) | 6 (6.1%) | |
| NR | 30 (30.3%) | 23 (23.2%) | |
| HLA typing | 1.000 | ||
| HLA matched | 51 (51.5%) | 51 (51.5%) | |
| HLA mismatched | 48 (48.5%) | 48 (48.5%) | |
| Conditioning | 0.200 | ||
| Bu-based | 51 (51.5%) | 42 (42.4%) | |
| TBI-based | 48 (48.5%) | 57 (57.6%) | |
| Donor source | 0.567 | ||
| PBSC | 53 (53.5%) | 57 (57.6%) | |
| PBSC + BM | 46 (46.5%) | 42 (42.4%) | |
| GVHD prevention | 0.886 | ||
| CsA + MTX or CsA + MTX + MMF | 42 (42.4%) | 43 (43.4%) | |
| CsA + MTX + MMF + ATG | 57 (57.6%) | 56 (56.6%) | |
| Grade of aGVHD | 0.771 | ||
| Grade 2 | 36 (36.4%) | 37 (37.4%) | |
| Grade 3 | 41 (41.4%) | 44 (44.4%) | |
| Grade 4 | 22 (22.2%) | 18 (18.2%) | |
| No. of aGVHD involved organs | 0.589 | ||
| 1 | 25 (25.3%) | 29 (29.3%) | |
| 2 | 46 (46.5%) | 48 (48.5%) | |
| 3 | 28 (28.3%) | 22 (22.2%) | |
| aGVHD involved organs | 0.860 | ||
| Skin | 73 (73.7%) | 63 (63.6%) | |
| Liver | 43 (43.4%) | 46 (46.5%) | |
| Upper GI | 9 (9.1%) | 10 (10.1%) | |
| Lower GI | 79 (79.8%) | 77 (77.8%) | |
| Onset of aGVHD median days (range) | 30 (14–132) | 28 (16–124) | 0.736 |
GVHD graft-versus-host disease, SR steroid-resistant, MSCs mesenchymal stromal cells, AML acute myeloid leukemia, ALL acute lymphocyte leukemia, CR complete response, PR partial response, NR no response, HLA human leukocyte antigen, Bu busulfan, TBI total body irradiation, PBSC peripheral blood stem cells, BM bone marrow, CsA cyclosporine, MTX methotrexate, MMF mycophenolate mofetil, ATG antithymocyte globulin, GI gastrointestinal
*Others included myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), multiple myeloma (MM), non-hodgkin lymphoma (NHL) and other acute leukemia